drugset / Trial / NCT04536363
Cri Analog PG1 Effectiveness and Safety in Covid-19
RandomizedParallel-groupOpen-labelTreatment
Summary
The Clinical trial aim to evaluate the effectiveness and safety of the administration of the intravenous prostaglandin E1 analog in the reduction of mortality and complications of patients with COVID-19 diagnosis. Therefore the investigators propose an open randomized clinical trial in the Fundación Santa Fe de Bogota
Timeline
- Start
- 2020-12-03
- Primary completion
- 2020-12-03
- Completion
- 2020-12-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alprostadil | Unknown | 0.01 ug/kg | Intravenous |
| Background | Dexamethasone | Small molecule | 6 mg | Intravenous |
| Background | Enoxaparin sodium | Other / unclassified | 1 mg/kg | Subcutaneous |
| Background | Enoxaparin sodium | Other / unclassified | 40 mg | Subcutaneous |
| Background | Tocilizumab | Monoclonal antibody | 8 mg/kg | Intravenous |